Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis
- 1 May 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 32 (5) , S293-S297
- https://doi.org/10.1097/01.ccm.0000128445.95144.b8
Abstract
Inhibition of the tissue factor–factor VIIa complex reduces coagulation and inflammation in animal models of endotoxemia and sepsis and in patients with severe sepsis. However, the mechanism by which tissue factor–dependent activation of the coagulation cascade enhances inflammation is not known. We tested the hypothesis that coagulation proteases enhance inflammation during endotoxemia by activating protease-activated receptors (PARs) within the vasculature. We found that genetically modified mice expressing low levels of tissue factor exhibited reduced interleukin-6 expression and increased survival in a mouse model of endotoxemia compared with control mice. In contrast, hirudin inhibition of thrombin or a deficiency in either PAR-1 or PAR-2 did not affect interleukin-6 expression or mortality. However, combining hirudin treatment to inhibit thrombin signaling through PAR-1 and PAR-4 with PAR-2 deficiency reduced lipopolysaccharide-induced interleukin-6 expression and increased survival. Taken together, our results suggest that activation of multiple PARs by coagulation proteases enhances inflammation during endotoxemia.Keywords
This publication has 39 references indexed in Scilit:
- Novel strategies for the treatment of sepsisNature Medicine, 2003
- The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsisCritical Care Medicine, 2001
- How the protease thrombin talks to cellsProceedings of the National Academy of Sciences, 1999
- Disseminated Intravascular CoagulationNew England Journal of Medicine, 1999
- Delayed Treatment with Recombinant Human Tissue Factor Pathway Inhibitor Improves Survival in Rabbits with Gram‐Negative PeritonitisThe Journal of Infectious Diseases, 1998
- Active Site Inhibited Factor VIIa (DEGR VIIa) Attenuates the Coagulant and Interleukin-6 and -8, but not Tumor Necrosis Factor, Responses of the Baboon to LD100Escherichia coliBlood, 1998
- Prevention of Endotoxin-Induced Mortality by Antitissue Factor ImmunizationArchives of Surgery, 1996
- Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.Journal of Clinical Investigation, 1993
- Pathogenetic Mechanisms of Septic ShockNew England Journal of Medicine, 1993
- DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damageBlood, 1991